934568-20-4Relevant articles and documents
PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION
-
, (2016/08/23)
Provided herein are compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of Glucocorticoid Receptor (GR) translocation. Furthermore, the subject compounds and compositions are useful for the treatment of diseases involved in the hypothalamic-pituitary-adrenal (HPA) axis.
AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF
-
, (2015/03/16)
The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont
AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF
-
, (2013/04/10)
The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont
Synthesis and evaluation of 5-fluoro-2-aryloxazolo[5,4- b ]pyridines as β-amyloid PET ligands and identification of MK-3328
Harrison, Scott T.,Mulhearn, James,Wolkenberg, Scott E.,Miller, Patricia J.,O'Malley, Stacey S.,Zeng, Zhizhen,Williams Jr., David L.,Hostetler, Eric D.,Sanabria-Bohorquez, Sandra,Gammage, Linda,Fan, Hong,Sur, Cyrille,Culberson, J. Christopher,Hargreaves, Richard J.,Cook, Jacquelynn J.,Hartman, George D.,Barrow, James C.
, p. 498 - 502 (2011/09/14)
5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential 18F containing β-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human β-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of β-amyloid plaque load.
NOVEL SUBSTITUTED AZABENZOXAZOLES
-
, (2010/01/12)
The present invention relates to novel amyloid binding compounds and methods for measuring effects of the compounds, by measuring changes of amyloid plaque level in living patients. More specifically, the present invention relates to a method of using the